There has been significant interest, speculation and controversy about the potential health benefits of CBD.

The CBD-Intel Health hub provides access to our news briefings, data and research on developments related to the science behind CBD and health, from news of clinical trials to the latest rulings from key regulatory bodies such as the EU and the US FDA.

Regulatory tracker: current global regulation of CBD March

26th March 2021 - Regulatory trackers |

CBD-Intel’s newly upgraded global regulatory tracker, updated every month, now offers a deeper analysis of each regulatory area.

Use the tabs at the top of the map to select a specific regulatory field and click on an individual country to bring up much more detail in the panel below, including links to legislation and CBD-Intel’s coverage of that market.

The key below the map indicates the level of regulation for the selected country and regulatory field based on our in-house analysis.

How far-reaching an impact could the CJEU Kanavape decision have?

11th December 2020 - Blog |

The Court of Justice of the European Union’s (CJEU) decision in the Kanavape case will have a tremendous impact on the CBD industry in the European Union (EU). However, the breadth of its impact is not yet fully realised. A number of things must happen beforehand and it may come down to further court rulings before a […]

What impact will Black Friday sales have on the CBD sector?

27th November 2020 - Blog |

Overall it seems the industry – particularly in Europe – is not expecting much from Black Friday sales. European companies appear to consider CBD products more as health products that are requirement purchases throughout the year as opposed to lifestyle products that might be purchased as a one off during a special sales event. The situation may be slightly different in […]

How important is the CJEU decision on the Kanavape case?

20th November 2020 - Blog |

How important is the CJEU decision on the Kanavape case?  The judgement in favour of CBD from the Courts of Justice of the European Union (CJEU) will almost certainly have significant long-term consequences for the CBD industry in Europe. It will likely influence the European Commission (EC)’s further assessment of the question of whether CBD is […]

How is the novel food status of CBD progressing in Europe?

3rd July 2020 - Blog |

Several major developments have all happened at the same time for novel foods. Perhaps most importantly, one of the European Commission’s departments – the  Directorate-General for Health and Food Safety – has said it is holding sending any further non-synthetic CBD applications to the European Food Safety Authority for evaluation until it has determined whether CBD technically falls under the definition of a narcotic according to the 1961 UN Single Convention on Narcotic Drugs.

CBD is a relatively new ingredient on the health marketplace and interest in its potential benefits continues to grow and consumers are increasingly attracted to products that promise wellness benefits. It has attracted endorsement and investment from increasing numbers of celebrities and sports personalities. Names as big as, Jay-Z and Beyoncé are among those investing or launching their own CBD brands and Gwyneth Paltrow is calling cannabis a “hero ingredient of the future”.

With so much rising interest in cannabinoids and the continuing growth of the wellness trend, it’s easy to see why business is booming for some but industry stakeholders need to stay on the right side of complex regulatory pathways for the lawful marketing of appropriate cannabis-derived products.

Stay on top of the ever-changing regulatory landscape with our CBD-Intel Health hub. It provides access to our news briefings, data and reports on developments related to the science behind CBD and health, from news of clinical trials to the latest rulings from the US FDA.